A Phase 1 interventional study of [14C]-ITI-1284 in Healthy Volunteers, sponsored by Intra-Cellular Therapies, Inc.. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-16.
Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
ITI-1284-012 is an open-label, single-dose study to assess the mass balance recovery of radioactivity, and to evaluate the pharmacokinetics, safety and tolerability of ITI-1284 after a single subcutaneous dose of [14C]-ITI-1284 in healthy male subjects.
Intra-Cellular Therapies, Inc. is the lead sponsor of 41 studies on the registry; 12 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 11 (46%) have results posted.
First submitted before Intra-Cellular Therapies, Inc. became part of Johnson & Johnson.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: [14C]-ITI-1284
\[14C\]-ITI-1284 20 mg oral solution (not more than 22 μCi), subcutaneous administration
Mass balance recovery of total radioactivity in urine and feces combined
percentage of total radioactivity
Time frame: Day 1 up to Day 29
Pharmacokinetics: AUC0-t for total radioactivity
Area under the plasma drug concentration-time curve (AUC) from time zero to the last measurable concentration
Time frame: Day 1 up to Day 29
Pharmacokinetics: AUC0-t for ITI-1284
Area under the plasma drug concentration-time curve (AUC) from time zero to the last measurable concentration
Time frame: Day 1 to Day 8
Pharmacokinetics: Cmax for total radioactivity
Maximum plasma concentration
Time frame: Day 1 up to Day 29
Pharmacokinetics: Cmax for ITI-1284
Maximum plasma concentration
Time frame: Day 1 to Day 8
Pharmacokinetics: Tmax for total radioactivity
Time of maximum plasma concentration
Time frame: Day 1 up to Day 29
Pharmacokinetics: Tmax for ITI-1284
Time of maximum plasma concentration
Time frame: Day 1 to Day 8
Percentage of subjects with treatment-emergent adverse events
Time frame: Up to 30 days after the dose of study drug
Change from baseline in systolic and diastolic blood pressure
Time frame: Day 14
Change from baseline in ECG QT interval
Time frame: Day 14
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2025 to primary completion in Mar 2025, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deulumateperone
Intra-Cellular Therapies, Inc. →